The Texas A&M University System is playing an important role in federal efforts to quickly produce COVID-19 vaccines. In July, the government tasked Texas A&M’s Center for Innovation in Advanced Development and Manufacturing and its subcontractor, FUJIFILM Diosynth Biotechnologies (FDB), to mass-produce doses of a vaccine candidate for Novavax Inc. The center is set to begin manufacturing the vaccine for clinical trials by the end of 2020 and will commence bulk production in 2021 for any vaccine approved by the FDA.
“The Texas A&M System is ready to save lives and help protect the country,” said System Chancellor John Sharp ’72. “This whole project is a triple win: It’s a win for the Texas A&M System, a win for FDB and a win for the nation.” 
